Component

Intravenous NAD+ intervention in humans

Context-specific entity; species, compartment and exposure are stated on each claim.

3 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What it acts on

  1. The six-hour NAD+ infusion altered circulating breakdown products and urinary NAD/metabolite excretion, demonstrating substantial handling of administered material.

    Intravenous NAD+ intervention in humans → Human NAD metabolites after intravenous NAD source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary full text
    experimental_model
    Same 11-person human pilot.
    limitations
    Not a quantitative map of every tissue uptake route or evidence of rejuvenation.
    nutrient_topic
    NAD+ collection; molecular form, preparation, species, exposure and manipulation remain explicit. · NAD+
    plain_language
    Some infused material is broken down or excreted.
    primary_references
    A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD. · 2019 · https://pubmed.ncbi.nlm.nih.gov/31572171/ · DOI 10.3389/fnagi.2019.00257

    NAD+: compartmental supply, consumption and cross-nutrient mechanisms (2026-09-19) · lines 292–298

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Same 11-person human pilot. · source_derived_draft · unverified_draft

    ## nad-plus-iv-metabolites Some infused material is broken down or excreted. The six-hour NAD+ infusion altered circulating breakdown products and urinary NAD/metabolite excretion, demonstrating substantial handling of administered material. Model: Same 11-person human pilot. Limitations: Not a quantitative map of every tissue uptake route or evidence of rejuvenation. Evidence access: Primary full text A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD. · 2019 · https://pubmed.ncbi.nlm.nih.gov/31572171/ · DOI 10.3389/fnagi.2019.00257
    Complete structured claim and evidence

  2. In a randomized pilot with eight NAD+ recipients and three saline controls, 750 mg NAD+ over six hours produced a significant plasma NAD increase at the six-hour endpoint, with no significant early rise during the first two hours.

    Intravenous NAD+ intervention in humans → Human plasma NAD concentration source_derived_draftungraded
    Experimental context and source evidence
    availability_state
    biomarker_context Imported condition classification; unverified.
    evidence_access
    Primary full text
    experimental_model
    Human pilot; approximately 3 micromoles/minute; serial plasma and urine sampling.
    limitations
    Small pharmacokinetic study; disappearance from plasma does not prove intact tissue uptake or clinical benefit.
    nutrient_topic
    NAD+ collection; molecular form, preparation, species, exposure and manipulation remain explicit. · NAD+
    plain_language
    Infusion input and measured blood concentration need not rise together immediately.
    primary_references
    A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD. · 2019 · https://pubmed.ncbi.nlm.nih.gov/31572171/ · DOI 10.3389/fnagi.2019.00257
    trigger_kind
    biomarker_context Imported condition classification; unverified.

    NAD+: compartmental supply, consumption and cross-nutrient mechanisms (2026-09-19) · lines 284–290

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Human pilot; approximately 3 micromoles/minute; serial plasma and urine sampling. · source_derived_draft · unverified_draft

    ## nad-plus-iv-plasma Infusion input and measured blood concentration need not rise together immediately. In a randomized pilot with eight NAD+ recipients and three saline controls, 750 mg NAD+ over six hours produced a significant plasma NAD increase at the six-hour endpoint, with no significant early rise during the first two hours. Model: Human pilot; approximately 3 micromoles/minute; serial plasma and urine sampling. Limitations: Small pharmacokinetic study; disappearance from plasma does not prove intact tissue uptake or clinical benefit. Evidence access: Primary full text A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD. · 2019 · https://pubmed.ncbi.nlm.nih.gov/31572171/ · DOI 10.3389/fnagi.2019.00257
    Complete structured claim and evidence

  3. A retrospective commercial-clinic series compared six clients receiving 500 mg IV NAD+ with eight receiving 500 mg IV NR over four-day loading protocols; NAD recipients reported gastrointestinal symptoms, chest pressure or elevated heart rate and required longer infusions.

    Intravenous NAD+ intervention in humans → Symptoms during commercial IV NAD infusions source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary full text
    experimental_model
    Small nonrandomized retrospective clinical series.
    limitations
    Selection, infusion rate and clinic practices limit causal comparison; not efficacy evidence or an incidence estimate for all users.
    nutrient_topic
    NAD+ collection; molecular form, preparation, species, exposure and manipulation remain explicit. · NAD+
    plain_language
    Infusion tolerability is a separate question from whether NAD biomarkers rise.
    primary_references
    Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. · 2026 · https://pubmed.ncbi.nlm.nih.gov/41704678/ · DOI 10.3389/fragi.2026.1652582

    NAD+: compartmental supply, consumption and cross-nutrient mechanisms (2026-09-19) · lines 300–306

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Small nonrandomized retrospective clinical series. · source_derived_draft · unverified_draft

    ## nad-plus-iv-tolerability Infusion tolerability is a separate question from whether NAD biomarkers rise. A retrospective commercial-clinic series compared six clients receiving 500 mg IV NAD+ with eight receiving 500 mg IV NR over four-day loading protocols; NAD recipients reported gastrointestinal symptoms, chest pressure or elevated heart rate and required longer infusions. Model: Small nonrandomized retrospective clinical series. Limitations: Selection, infusion rate and clinic practices limit causal comparison; not efficacy evidence or an incidence estimate for all users. Evidence access: Primary full text Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. · 2026 · https://pubmed.ncbi.nlm.nih.gov/41704678/ · DOI 10.3389/fragi.2026.1652582
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards